Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Alpine Immune Sciences (NASDAQ:ALPN - Get Rating) had its price target upped by equities researchers at Wedbush to $25.00 in a note issued to investors on Thursday, Stock Target Advisor reports. Wedbush's price target points to a potential upside of 208.64% from the stock's current price.Alpine Immune Sciences Stock Performance

ALPN stock traded up $0.13 on Thursday, hitting $8.10. The company's stock had a trading volume of 11,165 shares, compared to its average volume of 96,079. The stock has a market cap of $246.25 million, a price-to-earnings ratio of -4.22 and a beta of 1.59. The company has a current ratio of 2.75, a quick ratio of 2.75 and a debt-to-equity ratio of 0.01. Alpine Immune Sciences has a 1 year low of $6.00 and a 1 year high of $14.40. The firm has a 50 day moving average of $8.42 and a two-hundred day moving average of $8.52. Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. TCG Crossover Management LLC acquired a new position in Alpine Immune Sciences in the fourth quarter worth $16,207,000. Paradigm Biocapital Advisors LP bought a new stake in Alpine Immune Sciences in the first quarter worth about $3,016,000. Walleye Capital LLC bought a new stake in Alpine Immune Sciences in the fourth quarter worth about $1,525,000. Lynx1 Capital Management LP bought a new stake in Alpine Immune Sciences in the fourth quarter worth about $17,478,000. Finally, Lazard Asset Management LLC acquired a new stake in Alpine Immune Sciences during the 2nd quarter worth about $39,000. Hedge funds and other institutional investors own 79.01% of the company's stock. Alpine Immune Sciences Company Profile (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.See AlsoGet a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)Why Medical Products Maker Repligen May Be A Potential Buy At 10%, Is Arbor Realty Trust Dividend Worth It? Investors Should Tune Into RF Industries 2 Reasons Netflix Might Have Just Bottomed OutMurphy USA Outperforming Other Mid-caps, But Is It A Buy Now?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Alpine Immune Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpine Immune Sciences wasn't on the list.

While Alpine Immune Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

ETF portfolio manager, Dave Gilreath offers a perspective on “dividend achievers” and why these deserve a role in your portfolio

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.